Journal
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Volume 105, Issue -, Pages 525-531Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2021.01.009
Keywords
Severe acute respiratory syndrome coronavirus 2; Coronavirus disease 2019; Intravenous immunoglobulin; Efficacy evaluation; Mortality
Categories
Funding
- Shanghai Association for Science and Technology [17,411,969,700]
- Shanghai Sailing Plan Program [19YF1441200]
Ask authors/readers for more resources
A retrospective study using propensity score matching found that intravenous immunoglobulin (IVIG) therapy did not provide additional benefits beyond standard treatment for non-severe COVID-19 patients.
Objectives: At the present time, there is an absence of any proven effective antiviral therapy for patients with coronavirus disease 2019 (COVID-19). The aim of this study was to assess the efficacy of intravenous immunoglobulin (IVIG) in non-severe patients with COVID-19. Methods: A retrospective study based on propensity score matching (PSM) was designed. Primary outcomes included the severity and mortality rates. Secondary outcomes included the duration of fever, virus clearance time, length of hospital stay, and use of antibiotics. Results: A total of 639 non-severe patients with COVID-19 were enrolled. Forty-five patients received IVIG therapy and 594 received non-IVIG therapy. After PSM (1:2 ratio), the baseline characteristics were well balanced between the IVIG group (n = 45) and control group (n = 90). No statistically significant difference was found between the IVIG group and control group in the duration of fever (median 3 vs 3 days, p = 0.667), virus clearance time (median 11 vs 10 days, p = 0.288), length of hospital stay (median 14 vs 13 days, p = 0.469), or use of antibiotics (40% vs 38.9%, p = 0.901). Meanwhile, compared to the IVIG group, no more patients in the control group progressed to severe disease (3.3% vs 6.6%, p = 0.376) or died (0 vs 2.2%, p = 0.156). Conclusions: In non-severe patients with COVID-19, no benefit was observed with IVIG therapy beyond standard therapy. (C) 2021 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available